ReachMD

Episodes 1-15 of 383

• • 

    

    David M. Simpson, MD

    Peer

  • 

    

    David R. Walega, MD

    Peer

  • 

    

    Eric J. Viel, MD, PhD

    Peer

  4

  

  RestartResume

  Case Studies Addressing Modern Care Challenges with Painful Diabetic Peripheral Neuropathy of the Feet

  Case Studies Addressing Modern Care Challenges with Painful Diabetic Peripheral Neuropathy of the Feet

• • 

    

    Carol Wysham, MD

    Peer

  • 

    

    Kristen Nadeau, MD, MS

    Peer

  0

  

  RestartResume

  Investigating the Link Between Type 2 Diabetes & Obesity

  Investigating the Link Between Type 2 Diabetes & Obesity
• 0

  

  RestartResume

  Exploring the Obesity Epidemic in Women Across the United States

  Exploring the Obesity Epidemic in Women Across the United States

• • 

    

    Erin D. Michos, MD, MHS, FACC, FAHA, FASE

    Peer

  • 

    

    Leslie Cho, MD

    Peer

  1

  

  RestartResume

  Clinician’s Update on Omega-3s in ASCVD Risk Reduction

  Clinician’s Update on Omega-3s in ASCVD Risk Reduction

  0.25 credits

• • 

    

    David M. Simpson, MD

    Peer

  • 

    

    Rory Abrams, MD

    Peer

  4

  

  RestartResume

  Capsaicin 8% Topical System: An Advancement in the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet

  Capsaicin 8% Topical System: An Advancement in the Treatment of Painful Diabetic Peripheral Neuropathy of the Feet

• • 

    

    David M. Simpson, MD

    Peer

  • 

    

    Jon T. Gertken, MD

    Peer

  • 

    

    Stephanie Simon, NP

    Peer

  3

  

  RestartResume

  Best Practices for Administering Prescription Strength Capsaicin for Painful DPN of the Feet

  Best Practices for Administering Prescription Strength Capsaicin for Painful DPN of the Feet

• • 

    

    David M. Simpson, MD

    Peer

  • 

    

    Serge Perrot, MD, PhD

    Peer

  2

  

  RestartResume

  Addressing Questions Regarding Long-Term Treatment with a TPRV1 Agonist for Painful DPN of the Feet

  Addressing Questions Regarding Long-Term Treatment with a TPRV1 Agonist for Painful DPN of the Feet

• • 

    

    Kevan C. Herold, MD

    Peer

  • 

    

    Andrea Steck, MD

    Peer

  • 

    

    Anette Gabriele Ziegler, MD

    Peer

  0

  

  RestartResume

  Changing Treatment Paradigms in Type 1 Diabetes:  Role of Anti-CD3 Targeted Therapy -

  Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D

  Changing Treatment Paradigms in Type 1 Diabetes:  Role of Anti-CD3 Targeted Therapy -

  Screening for Islet Autoantibodies in Children and Adolescents to Prevent/Delay T1D

  0.50 credits

• • 

    

    Eden Miller, DO

    Peer

  • 

    

    James O’Keefe, MD

    Peer

  1

  

  RestartResume

  Close to the Heart: The Impact of Cardiovascular Disease on Patients With Type 2 Diabetes

  Close to the Heart: The Impact of Cardiovascular Disease on Patients With Type 2 Diabetes

• • 

    

    Peter McCullough, MD

    Peer

  • 

    

    Rachel Pessah-Pollack, MD

    Peer

  1

  

  RestartResume

  Mortality of Cardio-Renal-Metabolic (CRM) Disorders: The Benefits of a Collaborative Care Approach

  Mortality of Cardio-Renal-Metabolic (CRM) Disorders: The Benefits of a Collaborative Care Approach

• • 

    

    Peter McCullough, MD

    Peer

  • 

    

    Rachel Pessah-Pollack, MD

    Peer

  1

  

  RestartResume

  Morbidity of Cardio-Renal-Metabolic (CRM) Disorders: Multifaceted Risk Factor Management

  Morbidity of Cardio-Renal-Metabolic (CRM) Disorders: Multifaceted Risk Factor Management

• • 

    

    Eden Miller, DO

    Peer

  • 

    

    James O’Keefe, MD

    Peer

  1

  

  RestartResume

  Close to the Heart: The Increasing Prevalence of Type 2 Diabetes and Associated Comorbidities

  Close to the Heart: The Increasing Prevalence of Type 2 Diabetes and Associated Comorbidities

• • 

    

    Rachel Pessah-Pollack, MD

    Peer

  • 

    

    Peter McCullough, MD

    Peer

  1

  

  RestartResume

  The CRM Systems and the Continuum of Disease Risk

  The CRM Systems and the Continuum of Disease Risk

• • 

    

    Eden Miller, DO

    Peer

  • 

    

    James O’Keefe, MD

    Peer

  1

  

  RestartResume

  Close to the Heart: Assessing Cardiovascular Risk Factors in Our Patients With Type 2 Diabetes

  Close to the Heart: Assessing Cardiovascular Risk Factors in Our Patients With Type 2 Diabetes

• • 

    

    Brett Nowlan, MD

    Peer

  6

  

  RestartResume

  Recognizing Metabolic Dysfunction as a Driver of Cardiovascular Risk

  Recognizing Metabolic Dysfunction as a Driver of Cardiovascular Risk

• 1
• 2
• 3
• …
• 25
• 26
• Next